Researchers in an article published in Health Affairs say the Food and Drug Administration reviews precision drugs, on average, 1.7 years faster than nonprecision therapies.
According to an InsideHealthPolicy report, the researchers discovered the FDA reviews also occur with less premarket evidence, something which they say could produce adverse risks and uncertain benefits.
The research also concluded that while the quicker reviews can hasten marketing and trim development costs, postmarket data would take years to collect.
Click here to read the full report on InsideHealthPolicy. (Paid subscription required)